Patents by Inventor James Ronald Gillig

James Ronald Gillig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
    Patent number: 10253041
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei Wu
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS
    Publication number: 20180118759
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Application
    Filed: July 21, 2016
    Publication date: May 3, 2018
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei WU
  • N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
    Patent number: 8044090
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: October 25, 2011
    Assignee: Eli Lilly
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR
    Publication number: 20090306110
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Application
    Filed: July 16, 2009
    Publication date: December 10, 2009
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • Benzenesulfonic acid indol-5-yl esters as antagonists of the 5ht receptor
    Patent number: 7230011
    Abstract: The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Michael Edward Flaugh, James Ronald Gillig, Lawrence Joseph Heinz, Joseph Herman Krushinski, Jr., Bin Liu, Marta Maria Pineiro-Nunez, John Mehnert Schaus, John Stanley Ward
  • Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
    Patent number: 7229987
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jochen Ammenn, James Ronald Gillig, Lawrence Joseph Heinz, Philip Arthur Hipskind, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Jr., James Arthur Nixon, Carsten Ott, Kenneth Allen Savin, Theo Schotten, Lawrence John Slieker, Nancy June Snyder, Michael Alan Robertson
  • N-(2-Arylethyl) benzylamines as antagonists of the 5-HTreceptor
    Patent number: 7157488
    Abstract: The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6 receptor. The present invention further provides a method of treating disorders associated with 5-HT6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: January 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • MCH receptor antagonists
    Patent number: 7132456
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases
    Type: Grant
    Filed: December 3, 2003
    Date of Patent: November 7, 2006
    Assignee: Eli Lilly and Company
    Inventors: James Ronald Gillig, Lawrence Joseph Heinz, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Nancy June Snyder
  • N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
    Publication number: 20040132800
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Application
    Filed: February 27, 2004
    Publication date: July 8, 2004
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
    Publication number: 20040102481
    Abstract: The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.
    Type: Application
    Filed: July 22, 2003
    Publication date: May 27, 2004
    Inventors: Sandra Ann Filla, Michael Edward Flaugh, James Ronald Gillig, Lawrence Joseph Heinz, Joseph Herman Krushinski, Bin Liu, Marta Maria Pineiro-Nunez, John Mehnert Schaus, John Stanley Ward